<< Back
Biologic therapy monitoring: IDKmonitor® Golimumab drug level, ELISA
Article number:
K 9656
Tests:
96 Tests
Incubation time:
1h, 1h, 10-20min
Volume:
10 µl
Matrix:
Serum, EDTA-plasma
Standards:
4,15-225 ng/ml
Method:
ELISA
The success of a TNFalpha blocker therapy e. g. in patients with inflammatory bowel diseases is dependent on the choice of the appropriate drug, an effective dosage and, when indicated, the administration of immunosuppressive medication. For an optimal individual control of these parameters, Immundiagnostik now offers the following contract analyses of TNFalpha blocker drug levels:
IDKmonitor® -determination of TNFalpha blocker drug levels
Contact for Immundiagnostik‘s IDKmonitor® TNFalpha blocker therapy contract analysis Jana Ruppert
IDKmonitor® -determination of TNFalpha blocker drug levels
- Specific ELISA analysis of TNFalpha blocker: drug level of Infliximab (e.g. Remicade®), drug level of Adalimumab (e.g. Humira®) or drug level of Golimumab (e. g. Simponi®)
- Drug level determination in serum and EDTA plasma
- High analytic sensitivity
- Regular monitoring of trough levels facilitates dosage adjustments and provides information about therapy failure
Contact for Immundiagnostik‘s IDKmonitor® TNFalpha blocker therapy contract analysis Jana Ruppert
